NRG. Nuclear for Life.
- Pioneering research into medicines
- 30.000 patients a day
- Climate neutral energy
Advancing Nuclear Medicine
NRG develops, radiates and ensures worldwide distribution of nuclear medicines.
We are the global market leader in producing nuclear isotopes (medical isotopes). Every day, more than 30,000 patients worldwide depend on our medical substances for their treatment. These medical isotopes are used for medical imaging techniques (PET and SPECT scans). Doctors then use them in the treatment of cancer and heart and vascular disease for example.
Ensuring Nuclear Performance
Safe, reliable and efficient nuclear technology.
Objective expertise. We can provide independent proof that an installation and process is in order. We guarantee nuclear top performance. Based on our knowledge and experience, we use nuclear solutions for people and the planet.
Our Facilities
At the Energy & Health Campus in Petten, we have a unique combination of nuclear installations.
30,000 patients a day
Our reactor in Petten is responsible for producing 35% of all medical isotopes worldwide and for 65% in Europe. This makes our reactor in Petten the biggest producer and supplier of isotopes in the world. With the development of isotopes from Petten, we help 30,000 people a day have a better life. This might be by detecting and treating cancer or for other disorders.
Visit our website 30000perdag.nl where we will be happy to tell you more.
Discover
Curious about all the facts and Fiction about Nuclear Energy?
Our 700 innovative and motivated employees are working towards a cancer-free world and a climate neutral energy supply.
Latest News
Today, Tractebel and NRG|PALLAS signed a Memorandum of Understanding to cooperate to support the new-build of nuclear power plants in the Netherlands. The signing was held at the Embassy of Belgium in The Hague in the presence of the Belgian Ambassador Her Excellency Mrs Anick van Calster - on the sidelines of the Belgium - Netherlands Nuclear Summit. At the picture from left Joost van den Broek, director Consultancy & Services NRG|PALLAS, Bertholt Leeftink CEO NRG|PALLAS, Her Excellency Mrs Anick van Calste; Philippe Van Troeye, CEO, Tractebel; Denis Dumont, Chief Global Nuclear Officer, Tractebel.
There currently is a worldwide shortage of medical isotopes, due to lower available reactor capacity because of scheduled maintenance and temporary outages of one of the European reactors. The High Flux Reactor (HFR) in Petten therefore started up a day early after maintenance to increase the availability of medical isotopes.